Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 19/7/2019
SIETES contiene 92793 citas

 
 
 1 a 6 de 6 
Presentar resultados
Seleccionar todas
1.
Eron JJ, Young B, Cooper DA, Youle M, DeJesus E, Andrade-Villanueva J, Workman C, Zajdenverg R, Fätkenheuer G, Berger DS, Kumar PN, Rodgers AJ, Shaughnessy MA, Walker ML, Barnard RJO, Miller MD, DiNubile MJ, Nguyen B-Y, Leavitt R, Xu X, Sklar P, for the SWITCHMRK1 and 2 investigators. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet 2010;375:396-407. [Ref.ID 87807]
2. Cita con resumen
Youle M, Cohen C, Katlama C, Kuritzkes D, Walmsley S. Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals. Lancet 2004;364:1036-7. [Ref.ID 71451]
3.
Lister RK, Youle M, Nair D R, Winder AF, Rustin M H A. Latent dysbetalipoproteinaemia precipitated by HIV-protease inhibitors. Lancet 1999;353:1678. [Ref.ID 45299]
4. Cita con resumen
Youle M, Trueman P, Simpson K. Health economics in HIV disease: a review of the European literature. Pharmacoeconomics 1999;15:1-12. [Ref.ID 43777]
5.
Lalezari JP, Stagg RJ, Kuppermann BD, Holland GN, Kramer F, Ives DV, Youle M, Robinson M, Drew L, Jafar TH. Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med 1997;126:257-63. [Ref.ID 31529]
6.
Mocroft A, Youle M, Morcinek J, Sabin CA, Gazzard B, Johnson MA, Phillips A N, for the Royal Free/Chelsea and Westminster Hospitals. Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. BMJ 1997;314:409-13. [Ref.ID 30970]
Seleccionar todas
 
 1 a 6 de 6